Loading...
Market
Will Russian mRNA cancer vaccine be approved by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Approval announcements from Russian health regulatory bodies
Story
Russian mRNA Cancer Vaccine, Free for Citizens, Set for 2025 Launch After Pre-Clinical Trials
Dec 26, 2024, 05:00 AM
Russian scientists have developed a personalized mRNA cancer vaccine, which has shown promising results in pre-clinical trials. The vaccine, developed by the University of Science and Technology Sirius and the Gamaleya National Research Center, is designed to be tailored to each patient's tumor, identifying unique genetic mutations known as neoantigens. These neoantigens are used to train the patient's immune system to recognize and attack cancer cells, utilizing an mRNA platform. The vaccine aims to suppress tumor development and metastasis, acknowledging that no two tumors are similar. Plans are in place to start human trials in September 2025, with the vaccine expected to be available to Russian citizens for free in 2025 at a cost of 3000 dollars per dose to the state. The development of this vaccine began in mid-2022 by the team behind Russia's Sputnik V Covid-19 vaccine.
View original story
Similar markets
No • 50%
Yes • 50%
EU Approval • 25%
WHO Approval • 25%
No Major Approval • 25%
US FDA Approval • 25%
U.S. FDA Approval • 25%
WHO Recognition • 25%
EU Approval • 25%
No International Recognition • 25%
India • 25%
Other • 25%
China • 25%
Brazil • 25%
70-79% efficacy • 25%
Below 70% efficacy • 25%
80-90% efficacy • 25%
Above 90% efficacy • 25%
